Katy Jeannot

15PUBLICATIONS
74CO-AUTHORS
Medical infection agents (incl. prions)Ship and platform structures (incl. maritime hydrodynamics)Medical bacteriologyColloid and surface chemistryMedical microbiology not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jul 10, 2026
Mechanisms involved in cefiderocol resistance in French Pseudomonas aeruginosa clinical strains.

|May 26, 2026
Bioinspired Antimicrobial Strategy: An Extremophile Deep Sea Peptide to Combat Cystic Fibrosis Infections Caused by Pseudomonas aeruginosa and Staphylococcus aureus.

|Oct 21, 2025
Contribution of mutational resistance mechanisms and acquired β-lactamases to cefiderocol/xeruborbactam susceptibility in Pseudomonas aeruginosa.

Lucía González-Pinto, María Antonia Gomis-Font, Gloria Pérez-Rodríguez

|Jan 22, 2025
Uncovering a new family of conserved virulence factors that promote the production of host-damaging outer membrane vesicles in gram-negative bacteria.

Audrey Goman, Bérengère Ize, Katy Jeannot

|Jan 08, 2025
National Cohort of Compassionate Use of Meropenem-Vaborbactam: No Benefit over Meropenem for Pseudomonas aeruginosa.

Aurélien Dinh, Alexandre Bleibtreu, Clara Duran

|Aug 06, 2024
Evaluation of EUCAST rapid antimicrobial susceptibility test directly from positive blood culture for Pseudomonas aeruginosa.

Cédric Lebreton, Damien Fournier, Katy Jeannot

Pageof 3

Frequent Collaborators

3 joint publications

Marc Maresca

2 joint publications

Clarisse Roblin

2 joint publications

Patrick Plésiat

2 joint publications

Yohann Couté